Evidence map›Paper›PMID 39478693›Full record

ArticleMolecular and clinical oncology2024

Efficacy and safety of second‑generation FLT3 inhibitors in acute myeloid leukemia: A systematic review and meta‑analysis of randomized controlled trials.

Wei-Ting Lin, Chien-Ming Chao, Cheng-Yao Lin, Ya-Ting Hsu, Sheng-Yen Hsiao, Teng-Song Weng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Leukemia cutis as the first manifestation of acute myeloid leukemia.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wei-Ting LinDepartment of Orthopedics, Chi Mei Medical Center, Tainan 710033, Taiwan, R.O.C.
Chien-Ming ChaoDepartment of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan 736402, Taiwan, R.O.C.
Cheng-Yao LinDepartment of Senior Welfare and Services, Southern Taiwan University of Science and Technology, Tainan 710301, Taiwan, R.O.C.
Ya-Ting HsuDivision of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704302, Taiwan, R.O.C.
Sheng-Yen HsiaoDivision of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan 736402, Taiwan, R.O.C.
Teng-Song WengDepartment of Pharmacy, Chi Mei Medical Center, Liouying, Tainan 736402, Taiwan, R.O.C.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is one of the most frequent forms of acute leukemia and the second most common leukemia subtype in adults. In 2020, the incidence of AML in the United States was estimated to be ~4 cases per 100,000 adults. The FMS-like tyrosine kinase 3 (

Indexed as

gilteritiniboverall survivalprolonged heart-rate corrected QT intervalquizartinibsecond-generation FMS-like tyrosine kinase 3 inhibitors

Identifiers

PMID39478693
PMCPMC11523226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.